Adaptive Launches Integration Between Clonoseq® and Epic
Thursday, September 14, 2023
Adaptive Biotechnologies Corporation (Nasdaq: ADPT) is a biotechnology company with a focus on leveraging the genetics of the adaptive immune system for clinical applications. The company recently announced the integration of its clonoSEQ® test into Aura, which is Epic's specialty diagnostics suite. This integration allows healthcare providers to easily order and review clonoSEQ minimal residual disease (MRD) testing results within the Epic electronic health record (EHR) system, streamlining the diagnostic process.
MRD, or minimal residual disease, is the term used to describe the small number of cancer cells that can persist in a patient's body during and after treatment, potentially leading to disease recurrence. ClonoSEQ is a unique FDA-cleared test designed to detect MRD in various settings, including bone marrow from patients with multiple myeloma or B-cell acute lymphoblastic leukemia (B-ALL), as well as blood or bone marrow from patients with chronic lymphocytic leukemia (CLL). Additionally, clonoSEQ is available as a CLIA-validated laboratory-developed test (LDT) for use in other lymphoid cancers and specimen types. The ability to monitor MRD is crucial in managing blood cancers, as it provides personalized insights into treatment response and guides clinical decisions.
Susan Bobulsky, Senior Vice President of Diagnostics at Adaptive Biotechnologies, highlighted the significance of the partnership with Epic EHR, a leading provider in the United States. This partnership aims to enhance the customer experience and drive wider adoption of the clonoSEQ test by simplifying the workflow involved in send-out tests. Positive feedback from early adopters and increasing interest from healthcare providers have prompted efforts to expand the availability of seamlessly integrated testing experiences in Epic for providers and patients across the country.
Since the establishment of the partnership in September 2022, clonoSEQ has been accessible to healthcare providers through Aura, Epic's specialty diagnostics suite. The integration with Epic's EHR system enables oncologists to access clonoSEQ MRD results and discrete data directly within patient records, leading to faster and more efficient decision-making. Patients also benefit from real-time insights into their disease status.
Flora Stondell, FNP-C, Nurse Practitioner Supervisor at UC Davis Comprehensive Cancer Center, emphasized that integrating clonoSEQ into their EHR system reduces administrative burdens and enhances personalized care based on MRD status and treatment response.
Alan Hutchison, Vice President at Epic, highlighted the importance of collaboration between providers and diagnostics labs in advancing personalized medicine. Making clonoSEQ available through Aura within Epic's ecosystem allows providers to seamlessly incorporate MRD test results into clinical decision-making, significantly impacting the care of patients with blood cancer.
Adaptive and Epic plan to continue expanding institutional access to clonoSEQ through Epic's EHR system. Medical practices interested in accessing clonoSEQ MRD testing directly via Epic can contact their Adaptive account representative or Adaptive's Account Operations team at [email protected].
clonoSEQ® is the first and only FDA-cleared in vitro diagnostic (IVD) test service designed to detect minimal residual disease (MRD) in various clinical scenarios, including bone marrow from patients with multiple myeloma (MM) or B-cell acute lymphoblastic leukemia (B-ALL), as well as blood or bone marrow from patients with chronic lymphocytic leukemia (CLL). Additionally, clonoSEQ is available as a CLIA-validated laboratory-developed test (LDT) for use in other lymphoid cancers and specimen types. MRD refers to the small number of cancer cells that can persist in the body during and after treatment.
clonoSEQ utilizes Adaptive Biotechnologies' immune medicine platform to identify and quantify specific DNA sequences present in malignant cells. This enables clinicians to assess and monitor MRD during and after treatment. The test provides standardized, accurate, and sensitive measurements of MRD, allowing physicians to predict patient outcomes, monitor response to therapy, track patients during remission, and anticipate potential relapses. MRD status, as measured by clonoSEQ, is recognized as a reliable indicator of clinical outcomes and therapy response in hematological malignancies such as CLL, MM, and ALL according to clinical practice guidelines.
